High Triglyceridemia Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “High Triglyceridemia Pipeline Review H1 2015” report to its store. The report provides an overview of the high triglyceridemia’s therapeutic pipeline.

High Triglyceridemia Therapeutics Pipeline Market

High Triglyceridemia Therapeutics Pipeline Market

The report “High Triglyceridemia – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for High Triglyceridemia. Triglycerides are the most ordinary form of fat in the body. Triglycerides are the main component in vegetable oils and animal fats. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/high-triglyceridemia-pipeline-review-h1-2015-market-report.html.

The report also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Companies discussed in this High Triglyceridemia – Pipeline Review, H1 2015 report include Acasti Pharma Inc., Actavis plc, Alnylam Pharmaceuticals, Inc., Arisaph Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca PLC, BASF SE, Cardax Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Essentialis, Inc., Isis Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Novartis AG, Pharmena SA, Poxel SA, Tekmira Pharmaceuticals Corp., Thetis Pharmaceuticals LLC.

High triglycerides are caused by obesity, kidney disease, poorly controlled diabetes, drinking a lot of alcohol, hypothyroidism and regularly eating more calories. High triglycerides usually don't cause symptoms. Drug profiles discussed in this report include ALN-AC3, ALN-ANG, ARI-3037MO, AS-1708727, bezafibrate ER, BioE-1115, CAT-2003, CDX-085, diazoxide choline CR, ISIS-APOCIIIRx, MAT-9001, NKPL-66, pradigastat sodium, PRC-4016, Small Molecule for Hypertriglyceridaemia, Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Small Molecules for Dyslipidemia and Hypertriglyceridemia, Synthetic Peptides for Dyslipidemic and Vascular Disorders, TKM-HTG, TP-101, TP-110, TP-252, TP-8252 and TRIA-662. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=269552. (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this “High Triglyceridemia – Pipeline Review, H1 2015” report include: Dec 23, 2014: Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission; Nov 12, 2014: Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001; Nov 10, 2014: Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001; Oct 29, 2014: Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001; Oct 20, 2014: Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia; Sep 30, 2014: Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014; Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results; Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C; Sep 04, 2014: Matinas BioPharma to Present at Three Investor Conferences in September; Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014.

Table of Contents

List of Tables
Number of Products under Development for High Triglyceridemia, H1 2015
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
High Triglyceridemia - Pipeline by Acasti Pharma Inc., H1 2015
High Triglyceridemia - Pipeline by Actavis plc, H1 2015
High Triglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015
High Triglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015
High Triglyceridemia - Pipeline by Astellas Pharma Inc., H1 2015
High Triglyceridemia - Pipeline by AstraZeneca PLC, H1 2015
High Triglyceridemia - Pipeline by BASF SE, H1 2015
High Triglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015
High Triglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015
High Triglyceridemia - Pipeline by Essentialis, Inc., H1 2015
High Triglyceridemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
High Triglyceridemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015
High Triglyceridemia - Pipeline by Novartis AG, H1 2015
High Triglyceridemia - Pipeline by Pharmena SA, H1 2015
High Triglyceridemia - Pipeline by Poxel SA, H1 2015
High Triglyceridemia - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015
High Triglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2015
Assessment by Monotherapy Products, H1 2015

Explore more reports on Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website